Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
about
The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targetsThe Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic ReviewTargeted Therapy in Biliary Tract CancersGenetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapiesSensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell CulturesTargeted therapy in biliary tract cancers-current limitations and potentials in the future.Update on the Diagnosis and Treatment of Cholangiocarcinoma.Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapyEfficacy and toxicities of adding molecular targeted agents to first-line chemotherapy in the treatment of advanced biliary tract cancer: a systematic review and meta-analysis.Gemcitabine-cisplatin versus gemcitabine-oxaliplatin doublet chemotherapy in advanced gallbladder cancers: a match pair analysis.Efficacy and safety of chemotherapy with or without targeted therapy in biliary tract cancer: A meta-analysis of 7 randomized controlled trials.Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trialsTreatment of advanced Gall bladder cancer in the real world-can continuation chemotherapy improve outcomes?Therapeutic options for intrahepatic cholangiocarcinomaGenomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma.Systemic Therapy of Cholangiocarcinoma.FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinomaMultidisciplinary Care of Patients with Intrahepatic Cholangiocarcinoma: Updates in Management.Indian Council of Medical Research consensus document for the management of gall bladder cancer.Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer.Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation.A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study.Chemotherapy for advanced biliary tract carcinoma: A meta-analysis of randomized controlled trials.Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinomaActivation or suppression of the immune response mediators in biliary tract cancer (BTC) patients: a systematic review and meta-analysisCombination of anti-L1 cell adhesion molecule antibody and gemcitabine or cisplatin improves the therapeutic response of intrahepatic cholangiocarcinomaMolecular genetics and targeted therapeutics in biliary tract carcinoma.The effects of buthionine sulfoximine on the proliferation and apoptosis of biliary tract cancer cells induced by cisplatin and gemcitabine.Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer.Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing.Dual-modality imaging demonstrates the enhanced antitumoral effect of herpes simplex virus-thymidine kinase/ganciclovir plus gemcitabine combination therapy on cholangiocarcinoma.Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.A long survivor with local relapse of hilar cholangiocarcinoma after R1 surgery treated with chemoradiotherapy: a case report and literature review.Nab-paclitaxel as alternative treatment regimen in advanced cholangiocellular carcinoma.Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma.Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma.A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers.Hilar cholangiocarcinoma: expert consensus statement.Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure.
P2860
Q26751224-E08D9888-25AE-4F8F-A9B5-F4AAD389ACBDQ26752321-5B850435-E275-4C07-AD04-C4888B1FC344Q26798443-3D851C20-2919-4AAB-A129-6E62757A4B03Q26852049-20D880E4-78F2-42DF-B9AD-89F1A9C00ADEQ28550991-D8B91C90-CBE9-4071-B6FE-B43026E51F5FQ30234532-173064A0-2866-456C-B41C-5C5A2C465335Q30238895-FA0E0525-F5EF-450B-9415-1B3B14645A71Q33417019-8384CF58-1EA0-4282-8799-6731BBEF8B78Q33436600-2287DF49-9C8D-48EA-9DF8-2681B9713667Q33439321-8348BDE8-2882-4C0F-8442-4E591A39CCBBQ33440859-B0BE08F5-880D-4F56-BA38-3BD62F84CBB9Q33556487-8671DC79-D050-46AA-A9AE-8BF51AF12886Q33593225-09A90FCD-9D7F-4425-B0BB-52236E99747EQ33621529-FED88227-31D2-458D-9B06-5D5928D912C8Q33888432-0029C76C-A8C9-4C99-A6A2-66BD7BFA83DEQ34551877-A14C9905-4A0D-460A-BFBA-7636133B2F5AQ35078039-A9181428-AD38-477A-BB1B-9F349699090FQ35674607-4B09F146-70C4-47EC-8FEA-41F85C146A38Q35769701-A6997CAF-FD48-41D3-9AA4-8414A42D5BACQ35828499-E45C9BB4-091E-4356-B548-EBB80ACA036AQ35921330-B4DAEF5D-4E1B-495D-9271-7429C3D2AF04Q35934963-94A48EC5-5CD6-4E8A-981A-AC7C4224E905Q36107068-9036D2DB-3BFD-43E6-A5D8-7A0986664DD9Q36109481-C8C3DE4A-8CB3-4661-9F1B-C69603C9FE50Q36260577-8964F848-F3FD-4BFA-A015-AAF769878D70Q36271598-6EC9D50A-78D7-48A9-8C22-13AC10A56DA0Q36488070-A2096D8F-CF94-4FBF-A759-CB57756964BEQ36502644-9BD19F69-8AE1-40A8-9986-55FF09F1D3A4Q36609503-5A192D70-7ED0-4E85-8B13-A5952142561DQ36860098-5C5C89E3-2978-4CB8-9014-8A55E66C5183Q36870198-A8B6578F-1075-45E7-989F-9CF3C40045DAQ37001522-026A9A05-331D-487A-AEF3-463070C92B23Q37017110-68717085-45BD-46C0-A21E-38742613CA82Q37062864-D496D17B-5F68-4D81-B333-B3EC45BD1744Q37131675-66A98138-830B-46DC-8259-970BECF1B9BEQ37566921-D6F95330-8A08-423A-A954-6F1DB7391DF9Q37588461-EE0E7E3F-7EA9-403C-A15C-E3A18EB157CEQ37639577-40523B2D-F2C1-4AED-846C-5E3C6AE4D545Q38546730-452E2FAA-BF5A-48FF-A9ED-BCE0B2AA193BQ38577917-63F723A2-7B33-43CD-9395-A61E0232E245
P2860
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Gemcitabine and oxaliplatin wi ...... non-comparative phase 2 trial.
@ast
Gemcitabine and oxaliplatin wi ...... non-comparative phase 2 trial.
@en
type
label
Gemcitabine and oxaliplatin wi ...... non-comparative phase 2 trial.
@ast
Gemcitabine and oxaliplatin wi ...... non-comparative phase 2 trial.
@en
prefLabel
Gemcitabine and oxaliplatin wi ...... non-comparative phase 2 trial.
@ast
Gemcitabine and oxaliplatin wi ...... non-comparative phase 2 trial.
@en
P2093
P50
P1433
P1476
Gemcitabine and oxaliplatin wi ...... non-comparative phase 2 trial
@en
P2093
BINGO investigators
Christelle de la Fouchardière
David Malka
Dominique Wendum
Eric Assenat
Eveline Boucher
Frédéric Viret
Jean-Frédéric Blanc
Julien Grenier
Laetitia Fartoux
P304
P356
10.1016/S1470-2045(14)70212-8
P577
2014-05-19T00:00:00Z